[A20-30] Riociguat (CTEPH) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2020
Project no.:
A20-30
Commission:
Commission awarded on 17.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Adults with chronic thromboembolic pulmonary hypertension (CTEPH) with WHO Functional Class II to III to improve exercise capacity. The CTEPH has to be inoperable or persistent or recurrent after surgical treatment.
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-31 | Riociguat (PAH) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G14-02 | Riociguat - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A23-57 | Riociguat (pulmonary arterial hypertension in children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |